Printer Friendly

SANDOZ NAMES RONALD SCHMID EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS

 SANDOZ NAMES RONALD SCHMID EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS
 NEW YORK, Aug. 17 /PRNewswire/ -- Sandoz Corporation today announced the appointment of Ronald E. Schmid as executive director, external affairs, effective Sept. 1, 1992.
 In his new position, Schmid will report to Daniel C. Wagniere, chief executive officer and vice chairman of the board of Sandoz Corporation. He will spend the remainder of 1992 acquainting himself with Sandoz's diverse U.S. operations, as well as Sandoz International in Basle, Switzerland.
 Effective Jan. 1, 1993, Schmid will assume the position of vice president, external affairs, replacing Craig D. Burrell, M.D., who will retire at that time. In this position, Schmid will have responsibility for directing the external affairs activities of the Sandoz Corporation.
 Schmid was formerly director of public and government affairs for Lederle Laboratories, a division of American Cyanamid Company, where his responsibilities included policy analysis, public affairs, government affairs, media relations, marketing communications and philanthropy.
 Prior to joining Lederle, Schmid was associate director of government relations at the Pharmaceutical Manufactures Association.
 "Ron's extensive expertise and experience will be of great assistance to Sandoz and its U.S. operating subsidiaries," said Daniel C. Wagniere, chief executive officer and vice chairman of the board of Sandoz Corporation.
 Schmid received his M.P.A. from New York University and his B.A. from Fordham University. He resides in Morristown, N.J., with his wife, Linda, and their children, Jay and Gena.
 Burrell will become a consultant to Sandoz Corporation dealing with a number of special projects and will report to Wagniere.
 -0- 8/17/92
 /CONTACT: James R. Simpson of Sandoz, 212-830-2444/ CO: Sandoz Corporation ST: New York IN: MTC SU: PER


SM-LR -- NY042 -- 0496 08/17/92 12:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1992
Words:288
Previous Article:NORD PACIFIC LIMITED ANNOUNCES SECOND QUARTER RESULTS
Next Article:THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
Topics:


Related Articles
REJEANGE NAMED TO HEAD STERLING WINTHROP PHARMACEUTICALS GROUP
SANDOZ PHARMACEUTICALS NAMES TIM ROTHWELL PRESIDENT AND CEO
CORANGE LIMITED APPOINTS DR. MAX LINK AS CHIEF EXECUTIVE OFFICER
DEVELOPER OF HUMAN ANTIBODIES JOINS PROTEIN DESIGN LABS
PHARMACEUTICAL EXECUTIVE MAX LINK ELECTED DIRECTOR OF PROTEIN DESIGN LABS
SANDOZ GROUP NAMES NEW CHIEF FINANCIAL OFFICER
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
MARK A. PULIDO NAMED CHIEF OPERATING OFFICER
CELGENE ELECTS NEW BOARD MEMBER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters